Strategic Analysis
Glaxosmithkline- UK
Business Unit- Vaccine and Medicine
Word Count- (3,050)
Executive Summary
GlaxoSmithKline is one of the major pharmaceutical companies in United Kingdom that continues to traverse the competitive and challenging pharmaceutical industry. This report gives insight on the analysis of the strategies used by GlaxoSmithKline (vaccines and medicine business unit) to be able to sustain its performance in the pharmaceutical industry. This report applies PESTLE model, Porter’s five-force model, and Value chain analysis as well as the SWOT analysis tools environment facing the company. The reports assess performance of GSK Company amid the economic downturns. Based on the findings, GSK has been able to harness its potential, in efforts of enhancing competitiveness in its production of medicines and vaccine, notwithstanding environmental forces affecting the company. This report has also identified challenges that GSK has experienced over the years. In particular, GSK is faced by challenging; political, social and economic environments that has affected its position in the competitive pharmaceuticals market. However, there is need for GSK to incorporate strategies focused at leveraging its performance, to ensure it remains relevant in the market.
TABLE OF CONTENTS TOC \o "1-3" \h \z \u 1. Introduction PAGEREF _Toc402358202 \h 12. External Environmental Analysis on Vaccine and Medicine Production PAGEREF _Toc402358203 \h 12.1 PESTLE Analysis PAGEREF _Toc402358204 \h 12.1.1 Political Factors PAGEREF _Toc402358205 \h 22.1.2 Economic Factors PAGEREF _Toc402358206 \h 22.1.3 Social-Cultural Factors PAGEREF _Toc402358207 \h 32.1.4 Technological Factors PAGEREF _Toc402358208 \h 32.1.5 Environmental Factors PAGEREF _Toc402358209 \h 32.1.6 Legal Factors PAGEREF _Toc402358210 \h 42.2 Porter 's 5 Forces PAGEREF _Toc402358211 \h 42.2.1 Threat of New Entrants PAGEREF _Toc402358212 \h 42.2.1 Threat of Substitutes PAGEREF _Toc402358213 \h 52.2.3 Bargaining Power
Business Unit- Vaccine and Medicine
Word Count- (3,050)
Executive Summary
GlaxoSmithKline is one of the major pharmaceutical companies in United Kingdom that continues to traverse the competitive and challenging pharmaceutical industry. This report gives insight on the analysis of the strategies used by GlaxoSmithKline (vaccines and medicine business unit) to be able to sustain its performance in the pharmaceutical industry. This report applies PESTLE model, Porter’s five-force model, and Value chain analysis as well as the SWOT analysis tools environment facing the company. The reports assess performance of GSK Company amid the economic downturns. Based on the findings, GSK has been able to harness its potential, in efforts of enhancing competitiveness in its production of medicines and vaccine, notwithstanding environmental forces affecting the company. This report has also identified challenges that GSK has experienced over the years. In particular, GSK is faced by challenging; political, social and economic environments that has affected its position in the competitive pharmaceuticals market. However, there is need for GSK to incorporate strategies focused at leveraging its performance, to ensure it remains relevant in the market.
TABLE OF CONTENTS TOC \o "1-3" \h \z \u 1. Introduction PAGEREF _Toc402358202 \h 12. External Environmental Analysis on Vaccine and Medicine Production PAGEREF _Toc402358203 \h 12.1 PESTLE Analysis PAGEREF _Toc402358204 \h 12.1.1 Political Factors PAGEREF _Toc402358205 \h 22.1.2 Economic Factors PAGEREF _Toc402358206 \h 22.1.3 Social-Cultural Factors PAGEREF _Toc402358207 \h 32.1.4 Technological Factors PAGEREF _Toc402358208 \h 32.1.5 Environmental Factors PAGEREF _Toc402358209 \h 32.1.6 Legal Factors PAGEREF _Toc402358210 \h 42.2 Porter 's 5 Forces PAGEREF _Toc402358211 \h 42.2.1 Threat of New Entrants PAGEREF _Toc402358212 \h 42.2.1 Threat of Substitutes PAGEREF _Toc402358213 \h 52.2.3 Bargaining Power
References: Bass, A. (2008) Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial, Chapel Hill, NC: Algonquin Books of Chapel Hill. BBC, (2012) GlaxoSmithKline to pay $3bn in US drug fraud scandal [Online]Available at: http://www.bbc.co.uk/news/world-us-canada-18673220[Accessed: 29 October 2014]. Company Spotlight, GlaxoSmithKline (2011) ‘PharmaWatch: CNS’, 10(5), pp. 27-34. Datamonitor: GlaxoSmithKline Plc. (2011) ‘GlaxoSmithKline, PLC SWOT Analysis,’ pp. 1-8. GlaxoSmithKline Plc SWOT Analysis (2014) ‘GlaxoSmithKline, PLC SWOT Analysis’, pp. 1-10. GlaxoSmithKline Plc SWOT Analysis. (2012) GlaxoSmithKline, PLC SWOT Analysis’, pp. 1-8. GlaxoSmithKline Plc SWOT Analysis. (2014) GlaxoSmithKline, PLC SWOT Analysis’, pp. 1-10. Griffin, R. W. (2012) Fundamentals of management.6th ed. Mason, OH: South-Western Cengage Learning. Ienciu, I. (2012) ‘Environmental Reporting and Corporate Governance for Ftse 100 Listed Companies,’ Annals of The University Of Oradea, Economic Science Series, 21(2), pp. 681-687. Juliano, R. L. (2013) ‘Pharmaceutical innovation and public policy: The case for a new strategy for drug discovery and development’, Science & Public Policy (SPP), 40(3), pp. 393-405. Koo, C., Koh, C, E, & Nam, K. (2004) ‘An Examination of Porter 's Competitive Strategies in Electronic Virtual Markets: A Comparison of Two On-line Business Models’, International Journal Of Electronic Commerce, 9(1), pp. 163-180. Morrow Jr., J. L., Sirmon, D. G., Hitt, M. A., & Holcomb, T. R. (2007) ‘Creating value in the face of declining performance: firm strategies and organizational recovery’, Strategic Management Journal, 28(3), pp. 271-283. Pestle Analysis, (2014) ‘Poland Country Profile’, pp. 14-46. Research and, M. (2012) Research and Markets: GlaxoSmithkline Consumer Healthcare Ltd.: Company Profile and SWOT Analysis. Business Wire (English). Robson, K. (2013) Service-ability create a customer centric culture and gain competitive advantage. 1st ed. Chichester, West Sussex, United Kingdom: Wiley. Shakhshir, G. (2014) ‘Positioning Strategies Development’, Annals of the University of Oradea, Economic Science Series, 23(1), pp. 979-988. Weise, K. (2013) ‘Company News: Apple, GlaxoSmithKline’, Alibaba Group, Starbucks, U.K. Internet Operators. Businessweek.Com, p. 24